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Abstract: As more evidence emerges supporting the possibility that non-steroidal anti-
inflammatory drugs, especially aspirin (acetyl salicylic acid), might have a role in the prevention 
and management in certain types of cancer, there have been several attempts to fabricate salicylic 
acid-based polymers that can be employed in the targeted therapy of tumours. The primary 
disadvantage so far has been in use of non-therapeutic polymeric backbones that constitute the 
majority of WKH WKHUDSHXWLF SDUWLFOH¶V VL]H The focus of this research is the creation of a 
biodegradable polymer consisting only of salicylic acid, and its use as the main building block in 
targeted nanotherapeutics that would consequently provide both high local dose and sustained 
release of the active moiety. In this work, we demonstrate the synthesis and degradation of 
                                                 
a
 Supporting Information is available online from the Wiley Online Library or from the author. 
polysalicylates, and modulation of their size and hydrolytic stability through formation of 
nanostructures.  
Introduction 
There is a growing body of evidence indicating that non-steroidal anti-inflammatory drugs 
(NSAIDs), particularly aspirin, may have a chemopreventive role in some types of tumours.1,2 
Results from meta-analyses of observational studies and randomised controlled trials suggest that 
the regular use of aspirin in cancer patients, specifically those with breast,3 colorectal,4 or 
prostate5,6 cancer inversely correlates with cancer incidence, as well as being linked to a decrease 
in relapse and mortality rates and a reduction in metastases.7 However, the mechanism by which 
aspirin exhibits its anti-tumour effects is still not fully understood, and both COX-dependent and 
-independent pathways have been proposed.8 
Since the prolonged exposure of aspirin carries certain risks such as gastrointestinal bleeding and 
cerebral haemorrhage even at low doses,9,10 there is an ongoing debate on the risk-benefit ratio of 
prescribing aspirin in cancer for chemoprevention, and hence there are currently no guidelines 
advocating such practice.11,12  
Because the anti-inflammatory effects of aspirin could be attributed to its hydrolysis by-product, 
salicylic acid (SA),13 there have been several studies focusing on the creation of SA-based 
polymers for the controlled release of the this molecule in high local doses.14±18 However, since 
the synthesis of these polymers involves conjugating SA to a poly(anhydride-esters) or 
poly(xylitol-adipate) backbone, the loading capacity of the active moiety is limited, and the effect 
of other components arising from degradation must also be considered. In our group, we are 
actively investigating high local dose drug delivery through the creation of polymers comprised 
primarily of drug molecules. 
The goal of this research is to develop a biodegradable polymer that comprises solely of SA to 
eventually create a particle with a high-loading capacity and sustained-release of the drug while 
taking advantage of the characteristics that can make nanoparticles more targeted towards cancer 
tissue and less likely to exert action on healthy tissues.19 This could enhance the therapeutic effects 
of salicylic acid in cancer patients while minimizing side effects. Herein, we discuss a method for 
synthesis of polysalicylate (PSA), and further conjugation with polyethylene glycol (PEG) to both 
improve biocompatibility, and lead to the formation of self-assembled nanostructures as possible 
targeted therapeutic particles. 
Results and Discussion 
1. Polysalicylates (PSA)  
1.1. Synthesis and Characterization 
Polysalicylate was prepared using a condensation polymerisation method proposed by White et 
al.20 in which salicylic acid is heated with acetic anhydride at high temperatures under a nitrogen 
atmosphere (in that report, the PSA was used as capping agents for polyphenylene ethers). This 
method gives a linear polymer of 15-50 repeating units of SA with an acetyl group on one end and 
a carboxyl group on the other. 
Based on this method, polysalicylates in our experiments were prepared by a two-stage process. 
The first stage involved heating salicylic acid with 1.1 equivalents of acetic anhydride under 
nitrogen while refluxing at temperatures ranging between 150-200ÛC for varying durations of time 
(6 to 24 hours). In the second stage, temperature was raised to 250-300ÛC, nitrogen was 
disconnected, and the acetic acid by-product was distilled away with vacuum assistance over 
periods of time ranging from 6 to 24 hours. Upon cooling, the polymer formed as a glassy solid 
that could easily be extracted from the reaction vessel. 
The resulting polysalicylates were longer given more elevated temperatures and longer reactions 
times, and were soluble in dichloromethane, tetrahydrofuran, dimethyl sulfoxide, and chloroform. 
Long chains were partially soluble in acetone while short chains showed good solubility in that 
solvent. The polymer was practically insoluble in water, ethanol, methanol, hexane, and diethyl 
ether. 
For the purpose of this study, we created a short polymer, with 9 repeating units of SA, by heating 
the monomer with acetic anhydride in the first stage at 150 ÛC for 20 hours, and at 250 ÛC for 16 
hours in the second stage. A lower molecular weight was targeted to facilitate degradation studies. 
The polymer was further purified by dissolving it in dichloromethane (DCM) and precipitating it 
with methanol. This helped in washing out the monomer along with the short chains, thus 
enhancing the polydispersity profile of the polymer. To create a block-copolymer, an acyl chloride 
of the polysalicylate was made by reacting the polymer with thionyl chloride.  The acyl chloride 
was then esterified under basic conditions with monomethyl polyethylene glycol (mPEG, Mn= 
1900) to create PSA-b-mPEG. 
 
Figure 1 - Reaction scheme for synthesising polysalicylates (PSA) and polysalicylates-polyethylene glycol (PSA-mPEG) co-
polymer. (1) Salicylic acid is heated with acetic anhydride under nitrogen and then vacuum is used to remove the resulting acetic 
acid leaving PSA as a glassy solid. (2) Polysalicyloyl chloride is prepared by heating PSA with thionyl chloride and DMAP as a 
catalyst. (3) The resulting polysalicyloyl chloride is then reacted with mPEG in the presence of DIPEA to give PSA-b-mPEG co-
polymer. 
1H NMR (400 MHz, CDCl3) and gel permeation chromatography (GPC) were used to characterise 
the resulting polymers. As illustrated in Figure 2, the NMR spectrum exhibits broadening of the 
peaks of the aromatic region (6.9 ± 8.3 ppm) typical for a polymer. By integrating the peak at 8.13 
ppm that belongs to one of the benzene ring hydrogen with the peak at 2.17 that belongs to the 
hydrogens of the acetyl end group the number of the salicylate repeating units in the polymer can 
be determined. 
 
Figure 2- 1H-NMR spectrum of PSA (above) and PSA-mPEG (below) in CDCl3.  
GPC with a refractive index detector was used to evaluate the average molecular weights and the 
polydispersity of the polymer. The number average molecular weight (Mn) was 688, the weight 
average molecular weight (Mw) was 1075, and the dispersity (Ĉ) was 1.56. The response vs 
retention time chromatograms as well as the differential molecular weight distributions (DMWD) 
are shown in Figure S1 and S2, respectively. 
1.2. Degradation 
In order to assess the biodegradability of the synthesised polymer, an accelerated degradation test 
was conducted in several media representing different semblances of biological conditions. 
Accurately weighed amounts of the polymer were separately added to water (pH §, sodium 
hydroxide (2 mol dm-3, pH §), phosphate-buffered saline (PBS, pH §7.4), 10% foetal bovine 
serum (FBS) in PBS (pH §, and 36 units mL-1 solution of porcine liver esterase (PLE) in PBS 
(pH §, giving suspensions in each case. Analysis was carried out using UV spectroscopy in 
the range of 200-360 nm and the concentration of SA released in each medium was compared to a 
solution of SA in the respective medium that corresponds to 100% degradation of the polymer 
(Figure 3). Quantitative comparison was conducted at a wavelength of 296 nm. Initial degradation 
studies at 37 °C showed negligible release of SA, thus subsequent studies were conducted at a 
higher temperature to accelerate degradation. The polymer-containing media were hence incubated 
at 90ÛC, and samples from the supernatants were taken at different time points (2, 4, 8, 24, and 96 
hours) to measure the amount of SA released in each respective medium.  
The maximum release of SA observed with water was only about 5%, and a modest 11% release 
in enzyme-free PBS was also noted. High pH levels appeared to have the greatest effect on the 
SRO\PHU¶VHVWHUERQGVVLQFH an almost complete degradation happened with the NaOH solution 
after only 2 hours. The polymer showed a promising SA release of 60% and 49% in FBS and PLE 
respectively after 96 hours, which could indicate that a more sustained release might be achieved 
in the biology where a similar enzymatic composition exists at a lower temperature. 
 Figure 3 - Degradation of PSA in PBS, NaOH, Water, PLE, and FBS over a period of 96 h at 90ÛC. 'LIIHUHQFHVLQWKHµ([SHFWHG¶
curves are due to their being measured in the different media. The graph in the right lower corner shows the release percentage 
as measured at the wavelength of 296 nm. 
It is worth noting that, even though high temperatures most likely lead to the denaturing of 
enzymes in FBS and PLE, Weingand-Ziade et al. demonstrated that denaturing might have a 
more complicated kinetic that is also pressure-dependent and that moderate pressure might 
actually protect enzymes from inactivation21. We speculate that the enzymatic activity of the 
media in our study might have been preserved in a related manner. 
2. Polysalicylate-block-mPEG Co-polymer 
2.1. Synthesis and Characterisation 
Conjugating nanoparticles with PEG, also known as PEGylation, can enhance the pharmacokinetic 
profile of chemical entities. PEG enhances the half-life of nanoparticles by increasing their 
hydrophilicity, as well as ³VWHDOWKing´ them against the reticuloendothelial system (RES) which 
reduces the chances of their scavenging22,23. Since PEG is hydrophilic, its conjugation to PSA will 
create an amphiphilic polymer which would be expected to self-assemble into nanoscale micellar 
structures. This kind of polymeric micelles is a promising form of drug delivery systems in terms 
of stability, release profile, and tumour targeting.24,25 Increasing the size of the constructs through 
self-assembly to the range of 100-200 nm can provide a level of passive tissue targeting and 
accumulation by taking advantage of the SK\VLRFKHPLFDO FKDQJHV LQ VROLG WXPRXUV¶
microenvironment.26±28 Creating the delivery system within this size range also have an important 
role in decreasing renal clearance and splenic filtration and thus further enhancing 
bioavailability.29 In our study, we synthesised a co-polymer of PSA and mPEG for the purpose of 
creating micelles as nanocarriers for targeted therapy that have the hydrophobic core consisting of 
the drug intended for delivery itself, i.e. the PSA, and a hydrophilic PEG shell that gives the 
micelles all the advantages mentioned above. 
We created a PEG conjugate of our polysalicylate polymer by the method mentioned above. The 
co-polymer was characterised using 1H NMR (400 MHz, CDCl3) and GPC (Fig. 2, S1, S2). 
Integrating the peak at 8.13 ppm that belongs to one of the hydrogens of the benzene ring with the 
3.55 ppm peak of the polyethylene glycol hydrogens showed a PSA:PEG ratio of 1:1.27 indicating 
a successful coupling, but with a residual amount of PEG which defied extraction. GPC analysis 
(Mn = 2998, Mw = 3315, Ð = 1.11) was in line with expected values. DMWD of the co-polymer is 
shown in Figure S2 along those of the polymer and the PEG. The shift of the co-polymer to the 
right indicates the successful coupling between the polymer and the PEG. 
Although 1H NMR and GPC data suggests the successful PEGylation of PSA, it also indicates that 
the purification process is not complete. This is due to the difficulty in removing the mPEG from 
the end product, and since this impurity could possibly cause some inaccuracy in the future 
degradation studies of the co-polymer, this issue will be examined carefully to avoid any 
inconsistencies. 
2.2. PSA-b-mPEG Micelles 
We took advantage of the fact that our co-polymer has a hydrophilic and a hydrophobic end to 
create simple micelles as a means for the delivery of polysalicylates to target tissues. 
Two solutions of polysalicylates in THF (1 and 10 mg/mL) were prepared. As they were being 
independently stirred in round-bottom flasks, de-ionised water was added dropwise to the solutions 
to form micelles until a 10-fold dilution was achieved. The resulting micelles were analysed using 
dynamic light scattering (DLS) immediately after preparation and after 24 and 48 hours. 
DLS analysis showed a uniform distribution of size with the mean of about 250-300 nm for both 
samples (Figure S3, S4). The analysis of the samples over the following 48 hours showed minor 
changes in size distribution and correlograms suggesting that the nanostructure were stable for at 
least that period of time. However, given the fact that the theoretical total length of two co-polymer 
molecules head-to-head would not exceed 30 nm the larger size indicates that the particles formed 
by the micellisation process are vesicular rather than star micelles. This was corroborated using 
the transmission electron microscopy (TEM) after staining with 2% solution of uranyl acetate 
(Figure 4). The images indicated that unilamellar and multilamellar spheres of sizes consistent 
with the DLS results were formed. 
Degradation studies on the micelles was complicated by a difficult deconvolution of the spectrum 
of free PSA from that of the nanostructures in solution, hampering our attempts to accurately 
examine the kinetics of the system under different conditions at this stage. 
 
Figure 4 - PSA-mPEG particles as observed with TEM after staining with uranyl acetate.  
Conclusion 
We have shown that polymers comprised entirely of pharmaceutically active molecules can be 
synthesised, and moreover show sustained release of the active compound under biologically 
relevant conditions. By creating block copolymers, we can access prospectively biocompatible 
forms of the system which show modulated release profiles. Polymeric micelles that have a high 
loading of salicylic acid in the form of a biodegradable, sustained-release polymer and that are 
both compatible with the organism and shielded from its clearance mechanisms due to its PEG 
shell might have a promising role in chemoprevention and increasing cancer survival especially 
when they fall in the preferable size range of approximately 100-200 nm that increases their ability 
to passively target and accumulate in cancer tumours. We are currently exploring the self-assembly 
phase diagram of the copolymers with respect to chain length and block ratio, which will we 
correlate with release profiles and pharmacological activity in cancer cell lines.  
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